MarketWatch
Citi tells investors it’s time to sell Moderna after 600%-plus stock gains
Revenue and profit forecasts fail to justify the hype baked into Moderna’s share price, according to Citi’s analysts.
MarketWatch
Revenue and profit forecasts fail to justify the hype baked into Moderna’s share price, according to Citi’s analysts.